Kumar U
Int J Mol Sci. 2025; 26(1.
PMID: 39796008
PMC: 11720483.
DOI: 10.3390/ijms26010152.
Nouh R, Kamal A, Abdelnaser A
Pharmaceutics. 2023; 15(4).
PMID: 37111637
PMC: 10146800.
DOI: 10.3390/pharmaceutics15041151.
Haddad F, Dokmak G, Karaman R
Life (Basel). 2022; 12(5).
PMID: 35629350
PMC: 9148011.
DOI: 10.3390/life12050682.
Montalant A, Carlsen E, Perrier J
Physiol Rep. 2021; 9(18):e15029.
PMID: 34558208
PMC: 8461027.
DOI: 10.14814/phy2.15029.
Carlsen E, Falk S, Skupio U, Robin L, Pagano Zottola A, Marsicano G
Nat Neurosci. 2021; 24(5):658-666.
PMID: 33737752
PMC: 7610740.
DOI: 10.1038/s41593-021-00818-4.
Cannabinoid-Based Medicines and Multiple Sclerosis.
Manera C, Bertini S
Adv Exp Med Biol. 2020; 1264:111-129.
PMID: 33332007
DOI: 10.1007/978-3-030-57369-0_8.
Tremor in Multiple Sclerosis-An Overview and Future Perspectives.
Makhoul K, Ahdab R, Riachi N, Chalah M, Ayache S
Brain Sci. 2020; 10(10).
PMID: 33053877
PMC: 7601003.
DOI: 10.3390/brainsci10100722.
Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.
Reddy V, Grogan D, Ahluwalia M, Lopes Salles E, Ahluwalia P, Khodadadi H
EPMA J. 2020; 11(2):217-250.
PMID: 32549916
PMC: 7272537.
DOI: 10.1007/s13167-020-00203-4.
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.
Gado F, Digiacomo M, Macchia M, Bertini S, Manera C
Medicines (Basel). 2018; 5(3).
PMID: 30111755
PMC: 6164967.
DOI: 10.3390/medicines5030091.
Spotlight on postural control in patients with multiple sclerosis.
Prosperini L, Castelli L
Degener Neurol Neuromuscul Dis. 2018; 8:25-34.
PMID: 30050386
PMC: 6053902.
DOI: 10.2147/DNND.S135755.
[What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor].
Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M
Nervenarzt. 2017; 88(12):1421-1427.
PMID: 29063261
DOI: 10.1007/s00115-017-0438-4.
Endocannabinoid system in neurodegenerative disorders.
Basavarajappa B, Shivakumar M, Joshi V, Subbanna S
J Neurochem. 2017; 142(5):624-648.
PMID: 28608560
PMC: 5669051.
DOI: 10.1111/jnc.14098.
Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.
Abbassian H, Whalley B, Sheibani V, Shabani M
Br J Pharmacol. 2016; 173(22):3196-3207.
PMID: 27545646
PMC: 5071561.
DOI: 10.1111/bph.13581.
Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?.
Stephens G
J Physiol. 2016; 594(16):4631-41.
PMID: 26970080
PMC: 4983615.
DOI: 10.1113/JP271106.
Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?.
Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens G, Shabani M
Neurotherapeutics. 2015; 12(4):778-87.
PMID: 26152606
PMC: 4604184.
DOI: 10.1007/s13311-015-0367-5.
The therapeutic potential of cannabinoids for movement disorders.
Kluger B, Triolo P, Jones W, Jankovic J
Mov Disord. 2015; 30(3):313-27.
PMID: 25649017
PMC: 4357541.
DOI: 10.1002/mds.26142.
Role of cannabinoids in multiple sclerosis.
Zajicek J, Apostu V
CNS Drugs. 2011; 25(3):187-201.
PMID: 21323391
DOI: 10.2165/11539000-000000000-00000.
Cannabinoids in health and disease.
Kogan N, Mechoulam R
Dialogues Clin Neurosci. 2008; 9(4):413-30.
PMID: 18286801
PMC: 3202504.
Cannabinoid-based medicines for neurological disorders--clinical evidence.
Wright S
Mol Neurobiol. 2007; 36(1):129-36.
PMID: 17952657
DOI: 10.1007/s12035-007-0003-4.
Cannabinoids and multiple sclerosis.
Pertwee R
Mol Neurobiol. 2007; 36(1):45-59.
PMID: 17952649
DOI: 10.1007/s12035-007-0005-2.
